Advertisement

Clinical Practice Guideline of Integrative Chinese and Western Medicine for Acute Myocardial Infarction

  • Peng-da Liao
  • Ke-ji Chen
  • Jun-bo Ge
  • Min-zhou ZhangEmail author
  • Clinical Practice Guideline of Integrative Chinese and Western Medicine for Acute Myocardial Infarction Working Group
Regulation and Guideline
  • 10 Downloads

Abstract

With increasing morbidity and mortality, acute myocardial infarction (AMI) has become one of the major causes of human death, leading to heavy burdens to individuals, families and society. Previous researches have found that though large amount of resources and great effort were devoted, no significant improvements were achieved in reducing the in-hospital mortality of AMI patients. Meanwhile, extensive studies about Chinese medicine (CM) have found that CM has special advantages in treating AMI patients. However, there is no standardized and unified clinical practice guideline (CPG) of CM for AMI. Therefore, a CPG with strict standard and generally acknowledgement is urgent to be established. This guideline was developed following the methodological process established by the World Health Organization Handbook for Guideline Development. Extensive search on clinical evidences including systematic review (SR), randomized controlled trial (RCT), observational study and case reports was launched, covering evidence of CM for AMI on several aspects, such as diagnosis, CM patterns, CM interventions on AMI and complications, cardiac rehabilitation and clinical pathway management. Besides, the application of Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach enabled the evaluation of evidence and formulation of grade of recommendation (GOR) and level of evidence (LOE). With the help of GOR and LOE, this CPG recommends the integrative CM and WM treatment method in AMI patients and provides useful information on medical decision for clinical physicians.

Keywords

acute myocardial infarction integrative Chinese and Western medicine clinical practice guideline 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Reference

  1. 1.
    White HD, Chew DP. Acute myocardial infarction. Lancet 2008;372:570–584.CrossRefPubMedGoogle Scholar
  2. 2.
    Yeh RW, Sidney S, Chandra M, et al. Population trends in the incidence and outcomes of acute myocardial infarction. New Engl J Med 2010;362:2155.CrossRefPubMedGoogle Scholar
  3. 3.
    Rogers WJ, Frederick PD, Stoehr E, et al. Trends in presenting characteristics and hospital mortality among patients with ST elevation and non-ST elevation myocardial infarction in the national registry of myocardial infarction from 1990 to 2006. Am Heart J 2008;156:1026–1034.CrossRefPubMedGoogle Scholar
  4. 4.
    Li J, Li X, Wang Q, et al. ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data. Lancet, 2015;385:441–451.CrossRefPubMedGoogle Scholar
  5. 5.
    Moran A, Gu D, Zhao D, et al. Future cardiovascular disease in China: Markov model and risk factor scenario projections from the coronary heart disease policy model-China. Circulation 2010;3:243–252.PubMedGoogle Scholar
  6. 6.
    Liu H, Wang S, Yan L, et al. Characteristics and advantages of traditional Chinese medicine in the treatment of acute myocardial infarction. J Tradit Chin Med 2011;31:269–272.CrossRefPubMedGoogle Scholar
  7. 7.
    Chen KJ. Several problems in the study of syndrome differentiation and treatment of coronary heart disease. Chin J Intern Med (Chin) 1980;10:375–376.Google Scholar
  8. 8.
    Chen KJ, Qian ZH, Zhang WQ. Efficacy analysis among 112 cases of coronary heart disease and angina pectoris patients that treated by refined coronary heart tablets: double blind trial. Chin J Cardiol (Chin) 1982;10:85–89.Google Scholar
  9. 9.
    Chen KJ, Hui KK, Lee MS, et al. The potential benefit of complementary/alternative medicine in cardiovascular diseases. Evid Based Complement Alternat Med, 2012;2012:125029.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Chen KJ, Shi D Z, Xu H, et al. XS0601 reduces the incidence of restenosis: a prospective study of 335 patients undergoing percutaneous coronary intervention in China. Chin Med J 2006;119:6–13.CrossRefPubMedGoogle Scholar
  11. 11.
    Wang L, Zhang M, Guo L, et al. Clinical pathways based on integrative medicine in Chinese hospitals improve treatment outcomes for patients with acute myocardial infarction: a multicentre, nonrandomized historically controlled trial. Evid Based Complement Alternat Med 2012;2012:1–8.Google Scholar
  12. 12.
    Chen KJ, Zhang MZ, Huo Y. Expert consensus of diagnosis and treatment on integrative Chinese and Western medicine for acute myocardial infarction. Chin J Integr Tradit West Med (Chin) 2014;34:389–395.Google Scholar
  13. 13.
    World Health Organization. WHO handbook for guideline development. (2012-07-03) [2018-01-19]. Available at: https://doi.org/apps.who.int/iris/handle/10665/75146.
  14. 14.
    Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ 2010;182:E839–E842.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Brozek JL, Akl EA, Alonso-Coello P, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines: part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions. Allergy 2009;64:669–677.CrossRefPubMedGoogle Scholar
  16. 16.
    Brozek JL, Akl EA, Jaeschke R, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines: part 2 of 3. The GRADE approach to grading quality of evidence about diagnostic tests and strategies. Allergy 2009;64:1109–1116.CrossRefPubMedGoogle Scholar
  17. 17.
    Brozek JL, Akl EA, Compalati E, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines: part 3 of 3. The GRADE approach to developing recommendations. Allergy 2011;66:588–595.CrossRefPubMedGoogle Scholar
  18. 18.
    Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol 2012;60:1581–1598.CrossRefPubMedGoogle Scholar
  19. 19.
    Chen HZ, ed. Practical internal medicine, 14th ed. Beijing: People’s Medical Publishing House; 2013:1467–1494.Google Scholar
  20. 20.
    Chen HZ, ed. Practice of Cardiology, 5th ed. Shanghai: Science and Technology Publishing House; 2016:897–934.Google Scholar
  21. 21.
    Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018;39:119–177.CrossRefPubMedGoogle Scholar
  22. 22.
    Cornara S, Somaschini A, De Servi S, et al. Prognostic impact of in-hospital-bleeding in patients with ST-elevation myocardial infarction treated by primary percutaneous coronary intervention. Am J Cardiol 2017;120:1734–1741.CrossRefPubMedGoogle Scholar
  23. 23.
    Fox KA, Fitzgerald G, Puymirat E, et al. Should patients with acute coronary disease be stratified for management according to their risk? derivation, external validation and outcomes using the updated GRACE risk score. BMJ Open 2014;4:e4425.CrossRefGoogle Scholar
  24. 24.
    Satilmisoglu MH, Ozyilmaz SO, Gul M, et al. Predictive Values of D-dimer Assay, GRACE scores and TIMI scores for adverse outcome in patients with non-ST-segment elevation myocardial infarction. Ther Clin Risk Manag 2017;13:393–400.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Stub D, Smith K, Bernard S, et al. Air versus oxygen in ST-segment-elevation myocardial infarction. Circulation 2015;131:2143–2150.CrossRefPubMedGoogle Scholar
  26. 26.
    Hofmann R, James SK, Svensson L, et al. Determination of the role of oxygen in suspected acute myocardial infarction trial. Am Heart J 2014;167:322–328.CrossRefPubMedGoogle Scholar
  27. 27.
    ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345:669–685.CrossRefGoogle Scholar
  28. 28.
    Chinese Society of Cardiology, editorial board of Chinese Journal of Cardiology. Guideline for the diagnosis and treatment of acute ST elevation myocardial infarction. Chin J Cardiol (Chin) 2015;43:380–393.Google Scholar
  29. 29.
    Pizarro G, Fernandez-Friera L, Fuster V, et al. Long-term benefit of early pre-reperfusion metoprolol administration in patients with acute myocardial infarction: results from the METOCARD-CNIC trial (effect of metoprolol in cardioprotection during an acute myocardial infarction). J Am Coll Cardiol 2014;63:2356–2362.CrossRefPubMedGoogle Scholar
  30. 30.
    Roolvink V, Ibanez B, Ottervanger JP, et al. Early Intravenous beta-blockers in patients with ST-segment elevation myocardial infarction before primary percutaneous coronary intervention. J Am Coll Cardiol 2016;67:2705–2715.CrossRefPubMedGoogle Scholar
  31. 31.
    Yusuf S, Held P, Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am J Cardiol 1991;67:1295–1297.CrossRefPubMedGoogle Scholar
  32. 32.
    Held PH, Yusuf S, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ 1989;299:1187–1192.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Chinese Society of Cardiology, editorial board of Chinese Journal of Cardiology. Guideline for the diagnosis and treatment of non-ST-segment elevation acute coronary syndrome. Chin J Cardiol (Chin) 2017;45:359–376.Google Scholar
  34. 34.
    Steg PG, Bonnefoy E, Chabaud S, et al. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. Circulation 2003;108:2851–2856.CrossRefPubMedGoogle Scholar
  35. 35.
    Wiviott SD, Braunwald E, McCabe CH, et al; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001–2015.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045–1057.CrossRefGoogle Scholar
  37. 37.
    Fouda UM, Sayed AM, Abdou AM, et al. Enoxaparin versus unfractionated heparin in the management of recurrent abortion secondary to antiphospholipid syndrome. Int J Gynaecol Obstet 2011;112:211–215.CrossRefPubMedGoogle Scholar
  38. 38.
    Liu Z, Silvain J, Kerneis M, et al. Intravenous enoxaparin versus unfractionated heparin in elderly patients undergoing primary percutaneous coronary intervention: an analysis of the randomized ATOLL trial. Angiology 2017;68:29–39.CrossRefPubMedGoogle Scholar
  39. 39.
    Silvain J, Beygui F, Barthelemy O, et al. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. BMJ 2012;344:e553.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Cannon CP, Braunwald E, Mccabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495–1504.CrossRefGoogle Scholar
  41. 41.
    Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267–1278.CrossRefPubMedGoogle Scholar
  42. 42.
    Group AIMI. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. Circulation 1998;97:2202–2212.CrossRefGoogle Scholar
  43. 43.
    Pfeffer MA, Greaves SC, Arnold JM, et al. Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial. Circulation 1997;95:2643–2651.CrossRefPubMedGoogle Scholar
  44. 44.
    Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. trandolapril cardiac evaluation (TRACE) study group. N Engl J Med 1995;333:1670–1676.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Pfeffer MA, Mcmurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893–1906.CrossRefGoogle Scholar
  46. 46.
    Wang WW, Huang YS, Zhuo L, et al. Efficacy of Suxiaojiuxinwan vs. isosorbide dinitratein patients with angina pectoris: a meta-analysis. Chin J Evid Based Cardiovasc Med (Chin) 2015;7:298–303.Google Scholar
  47. 47.
    Cheng P, Li XY, Liu KQ, et al. Chinese experts’ suggestions on the clinical application of Compound Danshen Dripping Pills. Chin J Integr Tradit West Med (Chin) 2017;35:17–22.Google Scholar
  48. 48.
    Gao JF, Jiang YD, Zhan T, et al. Systematic review and meta-analysis of Shexiang Baoxin Pill in the treatment of unstable angina pectoris. J Pract Cardio Cerebrovascul Dis (Chin) 2011;9:2030–2033.Google Scholar
  49. 49.
    Zhang Y, Tang HX, Li J. Meta-analysis of Shexiang Baoxin Pill in treating coronary heart disease. Chin J Evid Based Cardiovasc Med (Chin) 2012;4:13–17.Google Scholar
  50. 50.
    Xu CX, Zhao YQ, Hu Y, et al. Systematic review on the treatment of coronary heart disease and angina pectoris with Shexiang Baoxin Pill. J China Pharm (Chin) 2011;22:4196–4200.Google Scholar
  51. 51.
    Fan WH, Wu ZG, Shi HM. Chinese experts consensus on Shexiang Baoxin Pill in treating coronary heart disease and angina pectoris. Chin J Integr Tradit West Med (Chin) 2018;32:145–153.Google Scholar
  52. 52.
    Li ZL, Dong GJ, Ge CJ, et al. A multicenter randomized controlled clinical trial on the alleviation effect of Kuanxiong Aerosol in treating coronary heart disease and angina pectoris. Chin J Integr Tradit West Med (Chin) 2014;34:396–401.Google Scholar
  53. 53.
    Li L, Li QY, Gu H, et al. Clinical observation on the treatment of coronary heart disease and angina pectoris treated with Kuanxiong Aerosol. Inf Tradit Chin Med (Chin) 2014;31:131–133.Google Scholar
  54. 54.
    LI J, ed. Chinese medical formulas, 9th ed. Beijing: Traditional Chinese Medicine Publishing House; 2006:1–291.Google Scholar
  55. 55.
    Jia ZH, Li YS, Wu YL, et al. Standardization research of diagnostic criteria on chinses syndrome for acute myocardial infarction. Chin J Integr Tradit West Med Intens Critic Care (Chin) 2007;14:195–199.Google Scholar
  56. 56.
    Wang L, He JZ, Zhang J, et al. An approach to law of distribution and evolvement of syndrome element during peri-reperfusion period on 218 patients with acute myocardial infarction. Chin J Integr Tradit West Med Intens Critic Care (Chin) 2010;17:267–270.Google Scholar
  57. 57.
    Wu W, Liu Y, Li R, et al. Retrospetive research on syndrome characteristics of acute myocardial infarction patients. J Guangzhou Univ Chin Med 2012;29:502–504.Google Scholar
  58. 58.
    Zhang MZ, Ding BH, Zhang WD, et al. Comparative study on coronary angiography results and Traditional Chinese Medicine syndromes of 375 chest pain patienst. Chin J Integr Tradit West Med Intens Critic Care (Chin) 2004;11:115–117.Google Scholar
  59. 59.
    Zhang MZ, ed. Chest stuffiness and coronary artery disease intervention. Beijing: Science Publishing House; 2007:1–366.Google Scholar
  60. 60.
    Mao C, Fu XH, Yuan JQ, et al. Tong-xin-luo Capsule for patients with coronary heart disease after percutaneous coronary intervention. Cochrane Database Syst Rev 2015;5:D10237.Google Scholar
  61. 61.
    Wu T, Harrison RA, Chen X, et al. Tongxinluo (Tong xin luo or Tong-xin-luo) Capsule for unstable angina pectoris. Cochrane Database Syst Rev 2006;4:D4474.Google Scholar
  62. 62.
    Chen W, Sun X, Wang WJ, et al. A multicenter clinical study on ventricular remodeling after myocardial infarction treated with Tongxinluo Capsule. Nat Med J China (Chin) 2008;88:2271–2273.Google Scholar
  63. 63.
    Tian ZT, Li HL, Li K. 30 cases of acute myocardial infarction after percutaneous coronary intervention treated with Tongxinluo Capsule. Chin J Exp Tradit Med Form (Chin) 2014;20:196–200.Google Scholar
  64. 64.
    Xu FK, Liu LB, Lv HT, et al. Clinical observation on the adjuvant treatment of coronary heart disease with Shexiang Tongxin Pill. Zhejiang J Integr Tradit Chin West Med (Chin) 2017;27:664–666.Google Scholar
  65. 65.
    Yang J, Zhang XW, Deng YP, et al. Research on vascular endothelial function improvement in coronary heart disease patients treated with Shexiang Tongxin Pill. Chin Arch Tradit Chin Med (Chin) 2016;34:2188–2190.Google Scholar
  66. 66.
    Wang Y, Niu ZC, He B, et al. Study on the mechanism of Shexiang Tongxin Pill to stabilize atherosclerotic plaque. Chin J Integr Med Cardio Cerebrovasc Dis (Chin) 2011;9:1083–1086.CrossRefGoogle Scholar
  67. 67.
    Liao PD, Wang L, Guo LH, et al. Danhong Injection (a traditional Chinese patent medicine) for acute myocardial infarction: a systematic review and meta-analysis. Evid Based Complement Alternat Med 2015;2015:646530.PubMedPubMedCentralGoogle Scholar
  68. 68.
    Mao S, Wang L, Zhao X, et al. Sodium tanshinone E A Sulfonate for reduction of periprocedural myocardial injury during percutaneous coronary intervention (STAMP trial): rationale and design. Int J Cardiol 2015;182:329–333.CrossRefPubMedGoogle Scholar
  69. 69.
    Qi H, Zhao X, Li YF. Apllication of sodium tanshinone II A sulfonate injection in acute myocardial infarction. China Med Herald (Chin) 2006;3(23):22–24.Google Scholar
  70. 70.
    Shanghai Cooperative Group for the Study of Tanshinone II A. Therapeutic effect of sodium tanshinone II A sulfonate in patients with coronary heart disease. A double blind study. J Tradit Chin Med (Chin) 1984;4:20–24.Google Scholar
  71. 71.
    Zheng G. Expert suggestions of clinical application on sodium tanshinone II A sulfonate injection. Chin J Geriatr Heart Brain Vessel Dis (Chin) 2015;17:1261–1264.Google Scholar
  72. 72.
    Kong D, Xia W, Zhang Z, et al. Safflower Yellow Injection combined with conventional therapy in treating unstable angina pectoris: a meta-analysis. J Tradit Chin Med (Chin) 2013;33:553–561.CrossRefGoogle Scholar
  73. 73.
    Zhang Y, Cao J, Huang DM, et al. Effect of Safflower Yellow Injection on platelet function in patients with coronary intervention. Shandong Med J (Chin) 2009;49:94–95.Google Scholar
  74. 74.
    Hu JH, Zhu WH, Ou Yuping, et al. Effect of Safflower Yellow Injection on high sensitivity C-reactive protein and platelet aggregation rate in patients with acute non-ST elevation myocardial infarction. J Clin Res (Chin) 2014;31:983–984.Google Scholar
  75. 75.
    Chen KJ, Fu CG, Cong WH, et al. Chinese expert consensus on clinical application of Safflower Yellow Injection. Chin J Integr Tradit West Med (Chin) 2017;37:1167–1173.Google Scholar
  76. 76.
    Qi JY, Wang L, Gu DS, et al. Protect effects of Danlou Tablet against murine myocardial ischemia and reperfusion injury in vivo. Chin J Integr Med 2018;24:613–620.CrossRefPubMedGoogle Scholar
  77. 77.
    Wang L, Zhao X, Mao S, et al. Efficacy of Danlou Tablet in patients with Non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results from a multicentre, placebo-controlled, randomized trial. Evid Based Complement Alternat Med 2016;2016:7960503.PubMedPubMedCentralGoogle Scholar
  78. 78.
    Wang SH, Wang J, Li J. Efficacy assessment of treating patients with coronary heart disease angina of phlegm and stasis mutual obstruction syndrome by Danlou Tablet. Chin J Integr Tradit West Med (Chin) 2012;2:1051–1055.Google Scholar
  79. 79.
    Wang SH, Wang J, Li J, et al. Therapeutic evaluation of Dan Lou Tablet in treating coronary heart disease and angina pectoris with pattern of binding of phlegm and stasis. Chin J Integr Tradit West Med (Chin) 2012;32:1051–1055.Google Scholar
  80. 80.
    Ren DZ, Zhang JR, Shen XL. Clinical observation of Dan Lou Tablet in the treatment of unstable angina pectoris with pattern of binding of phlegm and stasis. Chin J Integr Med Cardio Cerebrovasc Dis (Chin) 2014;12:1022–1023.Google Scholar
  81. 81.
    Luo J, Xu H, Chen K. Systematic review of Compound Danshen Dropping Pill: a Chinese patent medicine for acute myocardial infarction. Evid Based Complement Alternat Med (Chin) 2013;2013:808076.Google Scholar
  82. 82.
    Zhang MZ, Wang L, Chen BJ, et al. Meta-analysis of Compound Danshen Dripping Pill in treating stable angina pectoris. Chin J Integr Med Cardio/Cerebrovasc Dis (Chin) 2004;2:311–314.Google Scholar
  83. 83.
    Lu JH. Clinical Observation on 56 cases of aged coronary heart disease and angina pectoris treated with Danqi Soft Capsule. China Pract Med (Chin) 2012;7:124–125.Google Scholar
  84. 84.
    Sun ZW, Jiang ZG. Clinical observation of Danqi Soft Capsule on blood lipid regulation in coronary heart disease and hypertension. Chin J Conval Med (Chin) 2007;16:499–500.Google Scholar
  85. 85.
    Yang X, Xiong X, Yang G, et al. Songling Xuemaikang Capsule for primary hypertension: a systematic review of randomized controlled trials. Chin J Integr Med 2015;21:312–320.CrossRefPubMedGoogle Scholar
  86. 86.
    Nie YZ. Clinical application of Songling Xuemaikang Capsule. West China J Pharm Sci (Chin) 2007;22:718–720.Google Scholar
  87. 87.
    Dong ZN. Clinical application of Songling Xuemaikang Capsule in cardiovascular and cerebrovascular diseases. Chin J Integr Med Cardio Cerebrovasc Dis (Chin) 2015;13:896–898.Google Scholar
  88. 88.
    Cooperative Group of Study on the secondary prevention of coronary heart disease by adjusting serum lipids with Xuezhikang Capsule. China coronary secondary prevention study. Chin J Cardiol (Chin) 2005;33:109–115.Google Scholar
  89. 89.
    Li Y, Jiang L, Jia Z, et al. A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia. Evid Based Complement Alternat Med (Chin) 2014;9:e98611.Google Scholar
  90. 90.
    China Expert Consensus Group on the Clinical Application of Xuezhikang Capsule. Chinese expert consensus on the clinical application of Xuezhikang Capsule. Chin J Med (Chin) 2009;48:171–174.Google Scholar
  91. 91.
    Wang Y, Chen ZH, Liu GH, et al. Systematic review of randomized controlled trials of adjuvant treatment of coronary heart disease with Xuezhikang Capsule. Chin J Integr Tradit West Med (Chin) 2014;34:1182–1191.Google Scholar
  92. 92.
    Shang HC, Zhang JH, Yao C, et al. Qi-Shen-Yi-Qi Dripping Pills for the secondary prevention of myocardial infarction: a randomised clinical trial. Evid Based Complement Alternat Med 2013;2013:738391.PubMedPubMedCentralGoogle Scholar
  93. 93.
    Minicucci MF, Azevedo PS, Polegato BF, et al. Heart failure after myocardial infarction: clinical implications and treatment. Clini Cardiol 2011;34:410–414.CrossRefGoogle Scholar
  94. 94.
    Chen KJ, Wu ZG, Zhu MJ, et al. Expert Consensus of diagnosis and treatment in chronic heart failure with integrated traditional and Western medicine. Prev Treatm Cardio Cerebral Vasc Dis (Chin) 2016;16:142–145.Google Scholar
  95. 95.
    Zhang MZ, ed. Advance in cardiology in integrated traditional and Western medicine. Guangzhou: Sun Yat-Sen University Publishing House; 2012:1–409.Google Scholar
  96. 96.
    Tang XH. Cardiovascular action and therapeutic effect of Xinmailong Injection for treating heart failure. Chin J New Drugs (Chin) 2008;17:461–464.Google Scholar
  97. 97.
    Xue JG, Wang XL, Xu Y, et al. Treatment of chronic heart failure patients with qi-yang deficiency and blood stasis resistance syndrome by Xinmailong Injection: a multi-center randomized control study. Chin J Integr Tradit West Med (Chin) 2015;35:796–800.Google Scholar
  98. 98.
    Chinese Association of Integrative Medicine Cardiovascular Disease Professional Committee: Heart Failure Group. Expert consensus on standardized application of Xinmailong Injection in treating chronic heart failure. Chin J Integr Tradit West Med (Chin) 2016;36:280–284.Google Scholar
  99. 99.
    Li X, Zhang J, Huang J, et al. A multicenter, randomized, doubleblind, parallel-group, placebo-controlled study of the effects of Qili Qiangxin Capsules in patients with chronic heart failure. J Am Coll Cardiol 2013;62:1065–1072.CrossRefPubMedGoogle Scholar
  100. 100.
    Jiang T, Wang WW, Mei Y, et al. A Meta-analysis on curative effect of Qili Qiangxin Capsules on chronic heart failure. Chin J Evid Based Cardiovasc Med (Chin) 2015;31:868–874.Google Scholar
  101. 101.
    Hou YZ, Mao JY, Wang XL, et al. Systematic review on the efficacy and safety of Shenmai Injection in the treatment of heart failure. Chin J Evid Based Med (Chin) 2010;10:939–945.Google Scholar
  102. 102.
    Chen HD, Xie YM, Wang LX, et al. Systematic review on the efficacy and safety of Shenmai Injection in the treatment of chronic heart failure. China J Chin Mater Med (Chin) 2014;39:3650–3661.Google Scholar
  103. 103.
    Wen ZH, Nong YB, Pan CX, et al. Meta-analysis of clinical study on Huangqi Injection in the treatment of chronic heart failure. Chin J Integr Med Cardio Cerebrovasc Dis (Chin) 2011;9:770–772.Google Scholar
  104. 104.
    Wang SH, Mao JY, Hou YZ, et al. Route Western medicine treatment plus Qishen Yiqi Dripping Pill for treating patients with chronic heart failure: a systematic review of randomized control trails. Chin J Integr Tradit West Med (Chin) 2013;33:1468–1475.Google Scholar
  105. 105.
    Graf T, Desch S, Eitel I, et al. Acute myocardial infarction and cardiogenic shock: pharmacologic and mechanical hemodynamic support pathways. Coronary Artery Dis 2015;26:535–544.CrossRefGoogle Scholar
  106. 106.
    Zhang CY, LU Y, Zhang LD. The systematic evaluation and meta analysis of Shenfu Injection on acute myocardial infarction complication with cardiac shock. J Emerg Tradit Chin Med (Chin) 2015;24:1915–1917.Google Scholar
  107. 107.
    Yang QC, Mao W, Liu XS, et al. Systematic review on efficacy and safety of Shenfu Injection for cardiogenic shock. China J Tradit Chin Med Pharm (Chin) 2012;27:1052–1059.Google Scholar
  108. 108.
    Ye P. Application of Wenxin Granule in the treatment of arrhythmia after acute myocardial infarction. J Emerg Tradit Chin Med (Chin) 2013;22:1048–1049.Google Scholar
  109. 109.
    He Y, Liu Y, Zou AY. Meta-analysis on Wenxin Granules in treatment of arrhythmia. Chin Tradit Herb Drugs (Chin) 2014;45:2277–2282.Google Scholar
  110. 110.
    Heart Rhythm Society of the Chinese Society of Biomedical Engineering, Nao Xin Tong Zhi Committee of the Chinese Association of Integrative Medicine. Expert consensus on Wenxin Granule for treatment of cardiac arrhythmia. Chin Med J 2017;130:203–210.Google Scholar
  111. 111.
    Liu Y, Li N, Jia Z, et al. Chinese Medicine Shensongyangxin is effective for patients with bradycardia: results of a randomized, double-blind, placebo-controlled multicenter trial. Evid Based Complement Alternat Med (Chin) 2014;2014:605714.Google Scholar
  112. 112.
    Hu ZJ, Xu L, Wang QL, et al. Clinical curative effect analysis of Shensong Yangxin Capsule after acute myocardial infarction. J Prev Med Chin People Liber Army (Chin) 2016;34:S204–S205.Google Scholar
  113. 113.
    Hu H, Tang HX, Li JH, et al. Efficacy and safety of Shen Song Yang Xin Capsule for cardiac arrhythmia: a systematic review. Chin J Evid Based Med (Chin) 2011;11:168–173.Google Scholar
  114. 114.
    Zhang MZ, ed. DENG Tietao theroy in syndrome differentiation and treatment of coronary heart disease. Beijing: Science Publishing House; 2012:280.Google Scholar
  115. 115.
    Xuan J, Chen Y. Pathophysiology of coronary microcirculation and integrative treatment with Chinese and Western medicine. J Pract Tradit Chin Intern Med (Chin) 2012;26:90–91.Google Scholar
  116. 116.
    Shi ZX. Coronary microcirculation disorder and integrative treatment with Chinese and Western medicine. J China-Japan Friendship Hosp (Chin) 2005;19:362–364.Google Scholar
  117. 117.
    Zhang PA, Mei YX, Hu JJ, et al. Clinical observation of the long-term effect of tongxinluo capsule on the protection effect against coronary artery no-reflow after stent implantation in patients with acute myocardial infarction. Chin J Clin Rational Drug Use (Chin) 2015;8:38–39.Google Scholar
  118. 118.
    Liu JL, He YJ, Wu S, et al. Clinical observation of Tongxinluo Capsule on acute myocardial infarction after coronary stents with no-reflow. Chin J Difficult Complic Cases (Chin) 2014;13:80–82.Google Scholar
  119. 119.
    Zhang Y, Chen YD, Fu XH, et al. Chinese expert consensus on the diagnosis and treatment of coronary microvascular diseases. Chin Circul J (Chin) 2017;32:421–430.Google Scholar
  120. 120.
    You SJ, Yang YJ, Chen KJ, et al. Research of protective effect of Tongxinluo Capsule on myocardium and microvessels after reperfusion in patients with acute myocardial infarction. Chin J Cardiol (Chin) 2005;33:433–437.Google Scholar
  121. 121.
    Grech ED. ABC of Interventional cardiology: percutaneous coronary intervention. II: the procedure. BMJ 2003;326:1137–1140.CrossRefPubMedPubMedCentralGoogle Scholar
  122. 122.
    Liang GQ, Dai XH. Prevention and treatment of coronary restenosis after percutaneous coronary intervention treated by Chinese medicine. Clin J Tradit Chin Med (Chin) 2010;22:374–376.Google Scholar
  123. 123.
    Shi DZ, Xu FQ, Ma XC, et al. Research on the prevention and treatment of XueFuyu Concentrate Pill in rabbit coronary restenosis after percutaneous endovascular angioplasty. J Tradit Chin Med (Chin) 1997;38:685–687.Google Scholar
  124. 124.
    Fu DQ. Systematic review of Xiongshao Capsule in treating coronary heart disease after percutaneous coronary intervention [Dissertation]. Shanghai: Fudan University; 2013.Google Scholar
  125. 125.
    Lu XY. Research of Xiongshao Capsule improvement effect of vascular remodeling in treating in-stent restenosis after conronary artery intervention [Dissertation]. Beijing: Chinese Academy of Traditional Chinese Medicine; 2004.Google Scholar
  126. 126.
    Chen KJ, Shi DZ, Xu H. Effect of Xiongshao Capsule in preventing in-stent restenosis after intervention of coronary artery disease: a multicenter randomized double-blind placebo-controlled study[C]. Jilin, 2005Google Scholar
  127. 127.
    Chen KJ, Shi DZ, Xu H. Clinical research of Xiongshao Capsule in preventing in-stent restenosis after intervention of coronary artery disease[C]. Changchun, 2001.Google Scholar
  128. 128.
    Qi J, Yu J, Wang L, et al. Tongguan Capsule protects against myocardial ischemia and reperfusion injury in mice. Evid Based Complement Alternat Med (Chin) 2013;2013:159237.Google Scholar
  129. 129.
    Chen BJ, Feng JX, Su XX, et al. Effects of Tongguan Capsule on post-myocardial infarction ventricular remodeling and cardiac function in rats. Chin J Integr Med 2010;16:157–161.CrossRefPubMedGoogle Scholar
  130. 130.
    O’Connor GT, Buring JE, Yusuf S, et al. An overview of randomized trials of rehabilitation with exercise after myocardial infarction. Circulation 1989;80:234–244.CrossRefPubMedGoogle Scholar
  131. 131.
    Oldridge NB, Guyatt GH, Fischer ME, et al. Cardiac rehabilitation after myocardial infarction. Combined experience of randomized clinical trials. JAMA 1988;260:945–950.CrossRefPubMedGoogle Scholar
  132. 132.
    Yu ML, Chen KJ, Xu H. The future of cardiac rehabilitation: whole-process management, multiple integration, integration of Chinese and Western medicine. Chin J Integr Tradit West Med (Chin) 2017:1–4.Google Scholar
  133. 133.
    Bi YF, Mao JY, Zheng Y, et al. The status of cardiac rehabilitation in integrative with traditional Chinese medicine and Western medicine. Chin J Integr Med Cardio Cerebrovasc Dis (Chin) 2016;14:1616–1618.Google Scholar
  134. 134.
    Zou L, Sasaki JE, Wang H, et al. A systematic review and meta-analysis Baduanjin qigong for health benefits: randomized controlled trials. Evid Based Complement Alternat Med 2017;2017:4548706.CrossRefPubMedPubMedCentralGoogle Scholar
  135. 135.
    Pan HS. Study on the effects of baduanjin exercise on cardiopulmonary function in the elderly patients. J New Chin Med (Chin) 2008;40:55–57.Google Scholar
  136. 136.
    Chinese Society of Cardiology, Chinese Association of Rehabilitation Medicine Cardiovascular Disease Committee. Chinese experts’ consensus on coronary artery disease rehabilitation and secondary prevention. Chin J Cardiol (Chin) 2013;41:267–275.Google Scholar
  137. 137.
    Sun J, Liu PZ, Chen LR, et al. Clinical observation of balance needle in the treatment of acute myocardial infarction patients with chest pain. J Guangxi Univ Chin Med (Chin) 2014;17:49–51.Google Scholar
  138. 138.
    Liu DM, Zou JJ, Luo XM, et al. The therapeutic observation of high frequency electroacupuncture on acute myocardial infarction complicated with heart failure. J Sichaun Tradit Chin Med (Chin) 2014;32:146–149.Google Scholar

Copyright information

© The Chinese Journal of Integrated Traditional and Western Medicine Press and Springer-Verlag GmbH Germany part of Springer Nature 2019

Authors and Affiliations

  • Peng-da Liao
    • 1
    • 2
  • Ke-ji Chen
    • 3
  • Jun-bo Ge
    • 4
  • Min-zhou Zhang
    • 1
    • 2
    Email author
  • Clinical Practice Guideline of Integrative Chinese and Western Medicine for Acute Myocardial Infarction Working Group
  1. 1.Guangdong Provincial Hospital of Chinese MedicineGuangzhouChina
  2. 2.The Second Clinical College of GuangzhouUniversity of Chinese MedicineGuangzhouChina
  3. 3.Xiyuan HospitalChina Academy of Chinese Medical SciencesBeijingChina
  4. 4.Shanghai Institute of Cardiovascular Diseases Zhongshan HospitalFudan UniversityShanghaiChina

Personalised recommendations